Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMIN SCHADLU

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1962428276
CMS profile
224408
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$342.36

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $229.02 1
Food and Beverage $113.34 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Carl Zeiss Meditec, Inc. $229.02 1
Dutch Ophthalmic, USA $113.34 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMIN SCHADLU

NPI 1962428276 · CMS profile ID 224408

Allopathic & Osteopathic Physicians / Ophthalmology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMIN SCHADLU, NPI 1962428276, CMS profile ID 224408. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAMIN SCHADLU, NPI 1962428276, CMS profile ID 224408. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAMIN SCHADLU, NPI 1962428276, CMS profile ID 224408, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $342.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dutch Ophthalmic, USA $113.3403/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698426861 CMS
Carl Zeiss Meditec, Inc. $229.0203/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693206363 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $342.36 2
PY2022 $94.38 3
PY2023 $74.11 2
PY2025 $104.40 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $147,287.84 62
PY2024 Principal investigator $73,667.87 28
PY2023 Principal investigator $227,079.95 47
PY2022 Principal investigator $415,702.86 97
PY2021 Principal investigator $591,398.19 100
PY2020 Principal investigator $245,197.99 33
PY2019 Principal investigator $146,195.66 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

97 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $7,001.92 12/20/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950636371
Principal investigator 1 Genentech, Inc. $4,574.00 12/19/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950636493
Principal investigator 1 Genentech, Inc. $26,214.00 12/16/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950636937
Principal investigator 1 Genentech, Inc. $7,358.00 11/28/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 950638371
Principal investigator 1 Genentech, Inc. $40.83 11/15/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950700017
Principal investigator 1 Genentech, Inc. $113.79 11/15/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950700023
Principal investigator 1 Apellis Pharmaceuticals, Inc. $5,267.30 11/08/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285475
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $39,390.01 11/07/2022 Non-covered Recipient Entity
Doctrials Llc
BAY865321, HD 8mg, AMD - Ph 3 No dispute reported 06/30/2026 932266851
Principal investigator 1 Roche TCRC, Inc. $1,500.00 11/07/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950699069
Principal investigator 1 Genentech, Inc. $2,344.00 10/28/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 950640535
Principal investigator 1 Genentech, Inc. $19.66 10/27/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950706179
Principal investigator 1 Genentech, Inc. $22.71 10/25/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950706185
Principal investigator 1 Genentech, Inc. $694.14 10/11/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950642377
Principal investigator 1 Genentech, Inc. $3,474.00 09/28/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950644307
Principal investigator 1 Genentech, Inc. $41,393.00 09/28/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950645011
Principal investigator 1 Hexal AG $10,500.54 09/22/2022 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS RESEARCH LLC
CSOK583A12301 No dispute reported 06/30/2026 899867183
Principal investigator 1 Genentech, Inc. $2,118.00 08/26/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 950650119
Principal investigator 1 Genentech, Inc. $297.00 08/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950650819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,119.09 08/22/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938681289
Principal investigator 1 Genentech, Inc. $1,264.90 08/12/2022 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950653645
Principal investigator 1 Genentech, Inc. $469.00 08/11/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950719971
Principal investigator 1 Hexal AG $2,113.59 08/11/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899867241
Principal investigator 1 Genentech, Inc. $1,700.00 08/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 950654035
Principal investigator 1 Genentech, Inc. $4,978.96 08/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 950654041
Principal investigator 1 Genentech, Inc. $4,755.98 08/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950654107
Principal investigator 1 Genentech, Inc. $45.00 08/08/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950654449
Principal investigator 1 Genentech, Inc. $3,749.40 08/02/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950719977
Principal investigator 1 Genentech, Inc. $500.00 08/01/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950719982
Principal investigator 1 Genentech, Inc. $400.00 08/01/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950719987
Principal investigator 1 Roche TCRC, Inc. $3,254.00 07/29/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950725943
Principal investigator 1 Genentech, Inc. $500.00 07/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950719993
Principal investigator 1 Genentech, Inc. $16.96 07/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950719999
Principal investigator 1 Genentech, Inc. $13.66 07/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950720005
Principal investigator 1 Genentech, Inc. $500.00 07/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950720009
Principal investigator 1 Genentech, Inc. $4,529.00 07/22/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950656443
Principal investigator 1 Genentech, Inc. $2,344.00 07/20/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 950656749
Principal investigator 1 Hexal AG $1,500.00 07/07/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899867227
Principal investigator 1 Hexal AG $500.00 07/07/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899867235
Principal investigator 1 Genentech, Inc. $1,261.00 06/24/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950663171
Principal investigator 1 Genentech, Inc. $20,218.00 06/24/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950663645
Principal investigator 1 Genentech, Inc. $7,947.00 06/24/2022 Non-covered Recipient Entity
ARIZONA RETINA + VITREOUS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950663999
Principal investigator 1 Hexal AG $5,034.43 06/16/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866925
Principal investigator 1 Genentech, Inc. $1,021.00 06/06/2022 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 950666789
Principal investigator 1 Genentech, Inc. $4,236.00 05/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 950667701
Principal investigator 1 Roche TCRC, Inc. $1,583.00 05/24/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950744911
Principal investigator 1 Genentech, Inc. $783.73 05/17/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950732503
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,314.20 04/26/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285131
Principal investigator 1 Genentech, Inc. $13,698.90 04/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 950732509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $213.20 04/25/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938625047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,633.17 04/21/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938624297
Principal investigator 1 Roche TCRC, Inc. $434.30 04/19/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950744917
Principal investigator 1 Roche TCRC, Inc. $3,736.00 04/18/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950744923
Principal investigator 1 Roche TCRC, Inc. $8,948.80 04/18/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950744929
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,000.00 04/14/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285355
Principal investigator 1 Genentech, Inc. $7,487.00 04/13/2022 Non-covered Recipient Entity
DOCTRIALS LLC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 950675305
Principal investigator 1 Genentech, Inc. $20,775.00 03/29/2022 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950677565
Principal investigator 1 Hexal AG $7,691.96 03/17/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,374.80 03/17/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938618197
Principal investigator 1 Roche TCRC, Inc. $103.00 03/17/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747531
Principal investigator 1 Hexal AG $1,589.00 03/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866649
Principal investigator 1 Hexal AG $27.73 03/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866655
Principal investigator 1 Hexal AG $500.00 03/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,062.20 03/10/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938617843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 03/10/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938617845
Principal investigator 1 Apellis Pharmaceuticals, Inc. $53.41 03/03/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285029
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,889.18 03/03/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285351
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,889.18 03/03/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285353
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,044.98 03/03/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285473
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,044.98 03/03/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285673
Principal investigator 1 Hexal AG $142.07 03/03/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866645
Principal investigator 1 Genentech, Inc. $743.60 03/02/2022 Non-covered Recipient Entity
DOCTRIALS LLC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 950681389
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,673.28 02/28/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285471
Principal investigator 1 Genentech, Inc. $5,573.01 02/25/2022 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950681871
Principal investigator 1 Genentech, Inc. $4,236.00 02/25/2022 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 950682069
Principal investigator 1 Genentech, Inc. $550.00 02/25/2022 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 950682621
Principal investigator 1 Roche TCRC, Inc. $2,158.00 02/25/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747537
Principal investigator 1 Roche TCRC, Inc. $4,170.00 02/25/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747547
Principal investigator 1 Apellis Pharmaceuticals, Inc. $978.85 02/24/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285027
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,000.00 02/24/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285349
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,370.88 02/24/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 964285569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30.49 02/24/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938616385
Principal investigator 1 Genentech, Inc. $88.00 02/23/2022 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 950683389
Principal investigator 1 Genentech, Inc. $335.00 02/23/2022 Non-covered Recipient Entity
DOCTRIALS LLC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 950683645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,256.59 02/21/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938615945
Principal investigator 1 Genentech, Inc. $2,080.00 02/18/2022 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 950683811
Principal investigator 1 Roche TCRC, Inc. $105.63 02/15/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747553
Principal investigator 1 Roche TCRC, Inc. $1,309.90 02/15/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747565
Principal investigator 1 Hexal AG $74.49 02/10/2022 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 899866639
Principal investigator 1 Roche TCRC, Inc. $2,200.00 02/10/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747541
Principal investigator 1 Roche TCRC, Inc. $167.42 02/10/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747559
Principal investigator 1 Genentech, Inc. $7,817.50 01/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 950686917
Principal investigator 1 Genentech, Inc. $3,550.00 01/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 950687510
Principal investigator 1 Genentech, Inc. $22.22 01/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 950687609
Principal investigator 1 Genentech, Inc. $3,875.68 01/26/2022 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 950687719
Principal investigator 1 Genentech, Inc. $1,876.00 01/14/2022 Non-covered Recipient Entity
DOCTRIALS LLC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 950689141
Principal investigator 1 Roche TCRC, Inc. $21,907.80 01/14/2022 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 950747571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.86 01/03/2022 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 938612639